[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,534,780
  • Shares Outstanding, K 147,637
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,420 M
  • EBITDA $ 3,493 M
  • 60-Month Beta 0.20
  • Price/Sales 2.98
  • Price/Cash Flow 8.83
  • Price/Book 1.58

Options Overview Details

View History
  • Implied Volatility 34.24% (-0.08%)
  • Historical Volatility 32.02%
  • IV Percentile 48%
  • IV Rank 28.72%
  • IV High 50.85% on 10/16/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 4) 5.00 (2.50%)
  • Put/Call Vol Ratio 0.29
  • Today's Volume 824
  • Volume Avg (30-Day) 1,207
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 56,189
  • Open Int (30-Day) 54,846
  • Expected Range 195.05 to 205.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 35 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $3.36
  • Number of Estimates 21
  • High Estimate $4.40
  • Low Estimate $2.33
  • Prior Year $5.47
  • Growth Rate Est. (year over year) -38.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
184.90 +8.19%
on 06/02/26
205.97 -2.87%
on 05/13/26
+0.69 (+0.35%)
since 05/12/26
3-Month
168.64 +18.63%
on 04/06/26
205.97 -2.87%
on 05/13/26
+15.15 (+8.19%)
since 03/12/26
52-Week
121.05 +65.26%
on 07/21/25
205.97 -2.87%
on 05/13/26
+67.74 (+51.20%)
since 06/12/25

Most Recent Stories

More News
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 11, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc....

BIIB : 200.05 (+0.05%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK , June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...

BIIB : 200.05 (+0.05%)
How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

IBB : 170.66 (+0.10%)
AMGN : 355.20 (+0.32%)
BIIB : 200.05 (+0.05%)
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky

1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky

SAIA : 482.87 (-0.88%)
ORLY : 91.02 (+1.02%)
BIIB : 200.05 (+0.05%)
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 8, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc....

BIIB : 200.05 (+0.05%)
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or “the Company”) (NASDAQ:...

BIIB : 200.05 (+0.05%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...

BIIB : 200.05 (+0.05%)
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced slowing...

BIIB : 200.05 (+0.05%)
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower...

UCB.BB : 274.900 (+1.44%)
BIIB : 200.05 (+0.05%)
Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 29.82 (+1.57%)
BIIB : 200.05 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 207.04
2nd Resistance Point 205.24
1st Resistance Point 202.65
Last Price 200.05
1st Support Level 198.26
2nd Support Level 196.46
3rd Support Level 193.87

See More

52-Week High 205.97
Last Price 200.05
Fibonacci 61.8% 173.53
Fibonacci 50% 163.51
Fibonacci 38.2% 153.49
52-Week Low 121.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.